Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Anti-Vimentin Antibody-associated Diseases
NCT07051070Phase 4Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2025
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of rituximab in Vimentin IgG-Associated Autoimmune Meningoencephalomyelitis, sponsored by Xuanwu Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
Vimentin IgG-Associated Autoimmune Meningoencephalomyelitis
Beyond the preview
Go deeper on NCT07051070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07051070.